<clinical_study>
<study_id>
<org_name>
  Bayer
</org_name>
<org_full_name>
  Bayer
</org_full_name>
<org_study_id>
  100555
</org_study_id>
<nct_id>
  NCT00101400
</nct_id>
</study_id>
<is_fda_regulated>
  Yes
</is_fda_regulated>
<is_section_801>
  Yes
</is_section_801>
<delayed_posting>
  No
</delayed_posting>
<brief_title>
<textblock>
  BAY43-9006 - Phase II in Advance Breast Cancer
</textblock>
</brief_title>
<official_title>
<textblock>
  A Phase II Multicenter Uncontrolled Trial of BAY 43-9006 in Subjects With Metastatic Breast Cancer.
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  Bayer
</agency>
</lead_sponsor>
</study_sponsor>
<resp_party>
<name_title>
  Therapeutic Area Head
</name_title>
<organization>
  Bayer Spa
</organization>
</resp_party>
<oversight_info>
<regulatory_authority>
  United States: Food and Drug Administration
</regulatory_authority>
<has_dmc>
  No
</has_dmc>
</oversight_info>
<brief_summary>
<textblock>
  The purpose of this study is to evaluate the anti-cancer activity and safety of BAY 43-9006 (sorafenib) in patients, who suffer from an advanced breast tumour, which has spread to other organs of body despite treatment that the patient has received so far.
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
</textblock>
</detailed_descr>
<status_block>
<status>
  Completed
</status>
<date>
2009-07 
</date>
</status_block>
<start_date>
<date>
  2004-02
</date>
</start_date>
<last_follow_up_date
 type="Actual"
>
<date>
  2008-01
</date>
</last_follow_up_date>
<primary_compl_date
 type="Actual"
>
<date>
  2006-01
</date>
</primary_compl_date>
<phase_block>
<phase>
  Phase 2
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Non-Randomized
</design>
<design>
  Open Label
</design>
<design>
  Uncontrolled
</design>
<design>
  Single Group Assignment
</design>
<design>
  Safety/Efficacy Study
</design>
<number_of_arms>
  1
</number_of_arms>
<primary_outcome>
<measure>
  Number of Subjects With Response (Complete or Partial)
</measure>
<time_frame>
  Until 30 days after termination of active therapy
</time_frame>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<secondary_outcome>
<measure>
  Time to Progression
</measure>
<time_frame>
  Until progression occurs
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Time to Objective Response
</measure>
<time_frame>
  Until objective response occurs
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Overall Response Duration
</measure>
<time_frame>
  Time from  PR or CR  to progression
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Survival Time
</measure>
<time_frame>
  Start of treatment to death
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Number of Subjects With Stable Disease up to Cycle 4
</measure>
<time_frame>
  Until 30 days after termination of active therapy
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<enrollment
 type="Actual"
>
  54
</enrollment>
<condition>
  Cancer
</condition>
<condition>
  Breast Cancer
</condition>
<arm_group>
<arm_group_label>
  BAY 43-9006 400 mg b.i.d.
</arm_group_label>
<arm_type>
  Experimental
</arm_type>
<description>
<textblock>
  Sorafenib 400mg administered twice daily (b.i.d.)
</textblock>
</description>
</arm_group>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Nexavar (Sorafenib, BAY43-9006)
</primary_name>
<description>
<textblock>
  BAY 43-9006 400 mg b.i.d. daily
</textblock>
</description>
<arm_group_label>
  BAY 43-9006 400 mg b.i.d.
</arm_group_label>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion Criteria:
  - Age &gt; 18 years
  - Women with prior histologically documented diagnosis of breast cancer 
  - Subjects with metastatic disease who have already received and failed at least one chemotherapy regimen for metastatic disease and, if ER/PgR +ve, have failed on at least adjuvant hormonal therapy
  - Subjects for whom trastuzumab treatment is not indicated, no longer effective or refused by the subjects 
  - Four weeks since the last cytotoxic chemotherapy or clear evidence of progression on hormonal therapy 
  - Subjects who have at least one measurable lesion by CT(computed tomography) scan or MRI (magnetic resonance imaging) according to modified WHO Tumour Response Criteria
  - Subjects who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0, 1 or 2 
  - Adequate bone marrow, liver and renal function as assessed by the following laboratory evaluations: 
  - Hemoglobin &gt; 9.0 g/dl 
  - Absolute neutrophil count (ANC) &gt; 1,500/mm3 
  - Platelet count = 100,000/&#181;l 
  - Total bilirubin =1.5 x the upper limit of normal. 
  - ALT and AST = 2.5 x upper limit of normal (=5 x upper limit of normal for subjects with liver involvement of their cancer)
  - Amylase and lipase = 1.5 x the upper limit of normal
  - Serum creatinine = 3.0 x the upper limit of normal
  - PT or INR and PTT &lt; 1.5 x upper limit of normal (subjects who receive anti-coagulation treatment with an agent such as warfarin or heparin will be allowed to participate provided that no evidence of underlying abnormality in these parameters exists)
  - Subjects who give written informed consent prior to any study specific screening procedures with the understanding that the subject has the right to withdraw from the study at any time, without prejudice
  - Life expectancy of at least 12 weeks
  - Signed informed consent must be obtained prior to any study specific procedures
  Exclusion Criteria:
  - Previous malignancy (except for cervical carcinoma in situ, adequately treated basal cell carcinoma, or superficial bladder tumours [Ta, Tis and T1] or other malignancies curatively treated &gt; 2 years prior to entry) 
  - Congestive heart failure &gt; NYHA Class II 
  - Cardiac arrhythmia requiring anti-arrhythmic (excluding beta blockers or digoxin) 
  - Active coronary artery disease or ischaemia 
  - Active clinically serious bacterial or fungal infections (&gt; grade 2 National Cancer Institute - Common Toxicity Criteria  (NCI-CTC), Version 3) 
  - Known History of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C 
  - Metastatic brain or meningeal tumors unless the subject is &gt; 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry. Also the patient must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable provided that the dose is stable for 1 month prior to and following screening radiographic study)
  - Subjects with seizure disorders requiring medication (such as steroid or anti-epileptics) 
  - History of organ allograft 
  - Substance abuse, medical, psychological or social conditions that may interfere with the subject&apos;s participation in the study or evaluation of the study results 
  - Known or suspected allergy to the investigational agent 
  - Any condition that is unstable or which could jeopardize the safety of the subject and his/her compliance in the study. Pregnant or breast-feeding subjects. Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug. Women enrolled in this trial must use adequate barrier birth control measures during the course of the trial.
 
  Excluded therapies include: 
  - Anti -cancer chemotherapy, hormonal therapy or immunotherapy during the study or within 4 weeks of study entry. Mytomicin or nitroureas should not be given within 6 weeks of study entry
  - Significant surgery within 4 weeks prior to the start of study drug
  - Any bone marrow transplant or stem cell rescue within 4 months of the start of study drug 
  -Radiotherapy during the study or within 3 weeks of the start of drug 
  - Use of biologic response modifiers, such as G-CSF, within 3 weeks of study entry 
  - Investigational drug therapy outside of this trial during or within 30 days prior to start of the study drug 
  - Concomitant treatment with ketoconazole, itraconazole, ritonavir, or use of grapefruit juice 
  -Prior use of Raf-kinase inhibitors (RKI), MEK or farnesyl transferase inhibitors 
  - Concomitant treatment or use of St. John&apos;s Wort 
  - Prior use of bevacizumab and all other drugs that target VEGF/VEGF receptors
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<gender>
  Female
</gender>
<minimum_age>
  18 Years
</minimum_age>
<maximum_age>
</maximum_age>
</eligibility>
<investigator>
<role>
  Study Director
</role>
<name>
  Bayer Study Director
</name>
<affiliation>
<agency>
  Bayer
</agency>
</affiliation>
</investigator>
<contact>
<name>
  Bayer Clinical Trials Contact
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
  clinical-trials-contact@bayerhealthcare.com
</email>
</contact>
<contact>
<name>
  For trial location information (Phone Menu Options &apos;3&apos; or &apos;4&apos;)
</name>
<phone>
  (+)1-888-84 22937
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<location>
<facility>
<name>
</name>
<address>
<city>
  Stuttgart
</city>
<state>
  Baden-W&#252;rttemberg
</state>
<zip>
  70199
</zip>
<country>
  Germany
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
</name>
<address>
<city>
  M&#252;nchen
</city>
<state>
  Bayern
</state>
<zip>
  80637
</zip>
<country>
  Germany
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
</name>
<address>
<city>
  Frankfurt
</city>
<state>
  Hessen
</state>
<zip>
  60596
</zip>
<country>
  Germany
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
</name>
<address>
<city>
  Milano
</city>
<state>
</state>
<zip>
  20133
</zip>
<country>
  Italy
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
</name>
<address>
<city>
  Milano
</city>
<state>
</state>
<zip>
  20162
</zip>
<country>
  Italy
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
</name>
<address>
<city>
  Bologna
</city>
<state>
</state>
<zip>
  40138
</zip>
<country>
  Italy
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
</name>
<address>
<city>
  Parma
</city>
<state>
</state>
<zip>
  43100
</zip>
<country>
  Italy
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<see_also>
<annotation>
<textblock>
  Click here and search for drug information provided by the FDA
</textblock>
</annotation>
<url>
  http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm
</url>
</see_also>
<see_also>
<annotation>
<textblock>
  Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product
</textblock>
</annotation>
<url>
  http://www.fda.gov/medwatch/safety.htm
</url>
</see_also>
<see_also>
<annotation>
<textblock>
  Click here to find results for studies related to marketed products
</textblock>
</annotation>
<url>
  http://www.clinicalstudyresults.org
</url>
</see_also>
<initial_release_date>
  2005-01-10
</initial_release_date>
<last_release_date>
2009-07-21 
</last_release_date>
<init_disposition_release_date>
</init_disposition_release_date>
<init_results_release_date>
  2009-01-30
</init_results_release_date>
<clinical_result>
<baseline>
<baselinemeasures>
<baselinemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<dispersionspread>
  10.8
</dispersionspread>
<parametervalue>
  55.4
</parametervalue>
</reportedvalue>
</reportedvalues>
</measurecategory>
</measurecategories>
<parametertype>
  Mean
</parametertype>
<title>
  Age Continuous
</title>
<unitofmeasure>
  years
</unitofmeasure>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  54
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Female
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Male
</title>
</measurecategory>
</measurecategories>
<parametertype>
  Number
</parametertype>
<title>
  Gender, Male/Female
</title>
<unitofmeasure>
  participants
</unitofmeasure>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  30
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Grade 0: fully active
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  22
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Grade 1: Restricted strenous activity, ambulatory
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  2
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Grade 2: Ambulatory, difficulty in walking
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Grade 3: Limited self-care, partly confined to bed
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Grade 4: Completely disabled, no self-care
</title>
</measurecategory>
</measurecategories>
<measuredescription>
  5-point, ordinal scale specifying patient&apos;s ability to perform activities from 0 (fully active) to 4 (completely disabled, no self-care)
</measuredescription>
<parametertype>
  Number
</parametertype>
<title>
  Study Specific Characteristic
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<othertitle>
  Eastern Cooperative Oncology Group (ECOG) performance status
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage I
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage II
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage III
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  54
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage IV -most advanced
</title>
</measurecategory>
</measurecategories>
<measuredescription>
  Categorized information on tumor size, lymph node involvement and metastases. Overall cancer staging (I &#8211; IV) is based on the TNM categories. The higher the overall stage, the more advanced the cancer is.
</measuredescription>
<parametertype>
  Number
</parametertype>
<title>
  Study Specific Characteristic
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<othertitle>
  Stage of disease at study entry (tumor, nodules, metastasis (TNM) classification)
</othertitle>
</baselinemeasure>
</baselinemeasures>
<baselinereportinggroups>
<baselinereportinggroup
 id="Baseline-BaselineRptGroup.1"
>
<description>
  Sorafenib 400mg administered twice daily (b.i.d.)
</description>
<subjectsanalyzed>
  54
</subjectsanalyzed>
<title>
  BAY 43-9006 400 mg b.i.d.
</title>
</baselinereportinggroup>
</baselinereportinggroups>
<totalbaselinereportinggroup
 id="Baseline-TotalBaselineRptGroup"
>
<title>
  Total
</title>
</totalbaselinereportinggroup>
</baseline>
<certainagreement>
<otherdetails>
</otherdetails>
<pisponsoremployee>
  No
</pisponsoremployee>
<restrictiontype>
  GT60
</restrictiontype>
<restrictiveagreement>
  Yes
</restrictiveagreement>
</certainagreement>
<lastupdatetimestamp>
  2009-07-21T08:55:24-04:00
</lastupdatetimestamp>
<limitationsandcaveats>
<description>
  Subjects had advanced disease and were heavily pretreated.  Not all adverse events mentioned were assessed as drug-related. NCI-CTC was translated to Medical Dictionary for Regulatory Activities (MedDRA) for system organ classes (SOCs) only.
</description>
</limitationsandcaveats>
<outcomemeasures>
<outcomemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Complete response (CR)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Partial response (PR)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  20
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stable disease (SD)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  31
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Progressive disease (PD)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  2
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Not evaluated
</title>
</measurecategory>
</measurecategories>
<measuredescription>
  Number of subjects with metastatic breast cancer treated with single agent BAY 43-9006 who had best overall response assessed as complete response (CR) or partial response (PR) as per Modified World Health Organization (WHO) Tumor Response Criteria.
</measuredescription>
<parametertype>
  Number
</parametertype>
<timeframe>
  Until 30 days after termination of active therapy
</timeframe>
<title>
  Number of Subjects With Response (Complete or Partial)
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Primary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.1-OutcomeRptGroup.1"
>
<description>
  Sorafenib 400mg administered twice daily (b.i.d.)
</description>
<subjectsanalyzed>
  54
</subjectsanalyzed>
<title>
  BAY 43-9006 400 mg b.i.d.
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
  Intent to treat population consisted of subjects who received at least 1 dose of sorafenib.
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  95% Confidence Interval
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
  52
</dispersionlowerlimit>
<dispersionupperlimit>
  112
</dispersionupperlimit>
<parametervalue>
  58
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
  Time from start of treatment until progression was first documented.
</measuredescription>
<parametertype>
  Median
</parametertype>
<timeframe>
  Until progression occurs
</timeframe>
<title>
  Time to Progression
</title>
<unitofmeasure>
  days
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.2-OutcomeRptGroup.1"
>
<description>
  Sorafenib 400mg administered twice daily (b.i.d.)
</description>
<subjectsanalyzed>
  48
</subjectsanalyzed>
<title>
  BAY 43-9006 400 mg b.i.d.
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
  Of the intent to treat population, 4 subjects died before assessment of progression; for 1 subject the progression date not available; and 1 subject was lost to follow-up.
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionupperlimit>
</dispersionupperlimit>
<parametervalue>
  145
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
  Defined only for subjects achieving objective tumor response from start of treatment to the date when confirmed PR or CR was first documented according to the Modified WHO Tumor Response Criteria.
</measuredescription>
<parametertype>
  Number
</parametertype>
<timeframe>
  Until objective response occurs
</timeframe>
<title>
  Time to Objective Response
</title>
<unitofmeasure>
  days
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.3-OutcomeRptGroup.1"
>
<description>
  Sorafenib 400mg administered twice daily (b.i.d.)
</description>
<subjectsanalyzed>
  1
</subjectsanalyzed>
<title>
  BAY 43-9006 400 mg b.i.d.
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
  1 subject out of 54 achieved PR.
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionupperlimit>
</dispersionupperlimit>
<parametervalue>
  256
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
  Overall response duration was defined only for subjects achieving confirmed objective response (PR or CR). It was measured from start of treatment to the date when progressive disease was first objectively documented.
</measuredescription>
<parametertype>
  Number
</parametertype>
<timeframe>
  Time from  PR or CR  to progression
</timeframe>
<title>
  Overall Response Duration
</title>
<unitofmeasure>
  days
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.4-OutcomeRptGroup.1"
>
<description>
  Sorafenib 400mg administered twice daily (b.i.d.)
</description>
<subjectsanalyzed>
  1
</subjectsanalyzed>
<title>
  BAY 43-9006 400 mg b.i.d.
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
  1 subject out of 54 achieved PR.
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  95% Confidence Interval
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
  177
</dispersionlowerlimit>
<dispersionupperlimit>
  323
</dispersionupperlimit>
<parametervalue>
  259
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
  After the end of treatment visit (30 days after the last dose), the subjects were monitored every 3 months for survival (visits/phonecalls).
</measuredescription>
<parametertype>
  Median
</parametertype>
<timeframe>
  Start of treatment to death
</timeframe>
<title>
  Survival Time
</title>
<unitofmeasure>
  days
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.5-OutcomeRptGroup.1"
>
<description>
  Sorafenib 400mg administered twice daily (b.i.d.)
</description>
<subjectsanalyzed>
  54
</subjectsanalyzed>
<title>
  BAY 43-9006 400 mg b.i.d.
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
  Intent to treat population consisting of subjects who received at least 1 dose of sorafenib.
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  12
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
  Number of subjects who had not responded to treatment but had stable disease up to cycle 4.
</measuredescription>
<parametertype>
  Number
</parametertype>
<timeframe>
  Until 30 days after termination of active therapy
</timeframe>
<title>
  Number of Subjects With Stable Disease up to Cycle 4
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.6-OutcomeRptGroup.1"
>
<description>
  Sorafenib 400mg administered twice daily (b.i.d.)
</description>
<subjectsanalyzed>
  54
</subjectsanalyzed>
<title>
  BAY 43-9006 400 mg b.i.d.
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
  Intent to treat population consisting of subjects who received at least 1 dose of sorafenib.
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
</outcomemeasure>
</outcomemeasures>
<participantflow>
<participantflowgroups>
<flowgroup
 id="ParticipantFlow-ParticipantFlowGroup.1"
>
<description>
  Sorafenib 400mg administered twice daily (b.i.d.)
</description>
<title>
  BAY 43-9006 400 mg b.i.d.
</title>
</flowgroup>
</participantflowgroups>
<periods>
<period>
<completedmilestone>
<milestoneachievements>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<comment>
  Reasons for treatment termination: 4 Adverse Events, 3 Deaths, 46 Progression, 1 Withdrawal.
</comment>
<subjectsachieve>
  54
</subjectsachieve>
</milestoneachievement>
</milestoneachievements>
</completedmilestone>
<dropwithdrawreasons>
</dropwithdrawreasons>
<milestones>
</milestones>
<otherparticipantflowdetails>
<otherdetail>
<numbernotcompleted>
  0
</numbernotcompleted>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
</otherdetail>
</otherparticipantflowdetails>
<startedmilestone>
<milestoneachievements>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<comment>
  Treated until disease progression, unacceptable sorafenib-related toxicity or withrawal of consent.
</comment>
<subjectsachieve>
  54
</subjectsachieve>
</milestoneachievement>
</milestoneachievements>
</startedmilestone>
<title>
  Treatment
</title>
</period>
<period>
<completedmilestone>
<milestoneachievements>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<comment>
  44 subjects reached endpoint (death); 7 subjects were still alive
</comment>
<subjectsachieve>
  44
</subjectsachieve>
</milestoneachievement>
</milestoneachievements>
</completedmilestone>
<dropwithdrawreasons>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  7
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
  Alive
</otherreasonname>
<reasontype>
  Other
</reasontype>
</dropwithdrawreason>
</dropwithdrawreasons>
<milestones>
</milestones>
<otherparticipantflowdetails>
<otherdetail>
<numbernotcompleted>
  7
</numbernotcompleted>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
</otherdetail>
</otherparticipantflowdetails>
<startedmilestone>
<milestoneachievements>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<comment>
  3 subjects died during previous period (completion as defined in protocol)
</comment>
<subjectsachieve>
  51
</subjectsachieve>
</milestoneachievement>
</milestoneachievements>
</startedmilestone>
<title>
  Survival Follow-Up
</title>
</period>
</periods>
<preassignmentdescription>
  2 subjects were excluded during screening phase: 1 withdrawal of consent and 1 protocol violation.
</preassignmentdescription>
<recruitmentdetails>
  Subjects were enrolled from 03 Feb 2004 to 29 Jul 2004 by 3 centers in Germany and 4 centers in Italy.
</recruitmentdetails>
</participantflow>
<pointofcontact>
<email>
  clinical-trials-contact@bayerhealthcare.com
</email>
<organizationname>
  BAYER
</organizationname>
<phoneextension>
</phoneextension>
<phonenumber>
</phonenumber>
<title>
  Therapeutic Area Head
</title>
</pointofcontact>
<recordstatus>
  RELEASED
</recordstatus>
<reportedevents>
<frequencyreportingthreshold>
  20
</frequencyreportingthreshold>
<frequentadverseevents>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  27
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Fatigue
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  29
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Anorexia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  13
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Constipation
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  14
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Diarrhea
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  19
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Nausea
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  11
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Vomiting
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  16
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Pain, Other
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  11
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Cough
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  14
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Dyspnea (Shortness of Breath)
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  13
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Hand-Foot skin Reaction
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  15
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Pruritus
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  21
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Rash/Desquamation
</term>
</frequentevent>
</frequentadverseevents>
<interventiongroups>
<interventiongroup
 id="ReportedEvents-InterventionGroup.1"
>
<description>
  Sorafenib 400mg administered twice daily (b.i.d.)
</description>
<numsubjectsfrequentevents>
  50
</numsubjectsfrequentevents>
<numsubjectsseriousevents>
  22
</numsubjectsseriousevents>
<title>
  BAY 43-9006 400 mg b.i.d.
</title>
</interventiongroup>
</interventiongroups>
<seriousadverseevents>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Hemoglobin
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Supraventricular Arrythmia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Coagulation-Other
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Cardiac General-Other
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Death not associated with CTCAE term, Disease Progression
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Fever
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Fatigue
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Anorexia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Ascites
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Nausea
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Perforation, GI, Colon
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Vomiting
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Hepatobiliary disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Liver Dysfunction
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Hepatobiliary disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Hepatobiliary - Other
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Bilirubin (Hyperbilirubinemia)
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Hypercalcemia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Hyperkalemia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Dizziness
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Neuropathy: Motor
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  CNS Necrosis
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Neurology - Other
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Pain, Back
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Pain, Chest/Thorax NOS
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Pain Abdomen NOS
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Pain, Head/Headache
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Pleural Effusion
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Hypoxia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Pulmonary - Other
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Dyspnea (Shortness of Breath)
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Renal Failure
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  54
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Spontaneous Report
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  NCI-CTC 3.0
</sourcevocabulary>
<term>
  Erythema Multiforme
</term>
</seriousevent>
</seriousadverseevents>
</reportedevents>
</clinical_result>
</clinical_study>
